Genomics of clonal evolution in a rare essential thrombocythemia with coexisting Type 2 CALR and MPL S204P mutations

References

• Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–4. doi:10.1182/blood-2016-03-643544.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Kralovics R. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood. 2014;123(24):3714–3719. doi:10.1182/blood-2014-03-530865.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Pardanani A. Myeloproliferative neoplasms: a contemporary review. JAMA Oncol. 2015;1(1):97–105. doi:10.1001/jamaoncol.2015.89.
   PubMed Web of Science ®Google Scholar
• Jang MA, Seo MY, Choi KJ, Hong DS. A rare case of essential thrombocythemia with coexisting JAK2 and MPL driver mutations. J Korean Med Sci. 2020;35(23):e168. doi:10.3346/jkms.2020.35.e168.
   PubMed Web of Science ®Google Scholar
• Kang MG, Choi HW, Lee JH, Choi YJ, Choi HJ, Shin JH, Suh SP, Szardenings M, Kim HR, Shin MG. Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia. Oncotarget. 2016;7(35):57036–57049. doi:10.18632/oncotarget.10958.
   PubMedGoogle Scholar
• Jeromin S, Kohlmann A, Meggendorfer M, Schindela S, Perglerová K, Nadarajah N, Kern W, Haferlach C, Haferlach T, Schnittger S. Next-generation deep-sequencing detects multiple clones of CALR mutations in patients with BCR-ABL1 negative MPN. Leukemia. 2016;30(4):973–976. doi:10.1038/leu.2015.207.
   PubMed Web of Science ®Google Scholar
• Zhang QG, Wang J, Gong WY, Jing QC. Clonal evolution in a chronic neutrophilic leukemia patient. Hematology. 2019;24(1):455–458. doi:10.1080/16078454.2019.1613291.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang B, Chen B, Rf Z, Qg Z, Li J, Yang YG, Zhou M, Shao XY, Xu Y, et al. JAK2, MPL, and CALR mutations in Chinese Han patients with essential thrombocythemia. Hematology. 2017;22(3):145–148. doi:10.1080/10245332.2016.1252003.
   PubMed Web of Science ®Google Scholar
• Milosevic Feenstra JD, Nivarthi H, Gisslinger H, Leroy E, Rumi E, Chachoua I, Bagienski K, Kubesova B, Pietra D, Gisslinger B, et al. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood. 2016;127(3):325–332. doi:10.1182/blood-2015-07-661835.
   PubMed Web of Science ®Google Scholar
• Cabagnols X, Favale F, Pasquier F, Messaoudi K, Defour JP, Ianotto JC, Marzac C, Couédic Jp L, Droin N, Chachoua I, et al. Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood. 2016;127(3):333–342. doi:10.1182/blood-2015-07-661983.
   PubMed Web of Science ®Google Scholar
• Rumi E, Pietra D, Guglielmelli P, Bordoni R, Casetti I, Milanesi C, Sant’antonio E, Ferretti V, Pancrazzi A, Rotunno G, et al. Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative. Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. Blood. 2013;121(21):4388–4395. doi:10.1182/blood-2013-02-486050.
   PubMed Web of Science ®Google Scholar
• Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, Them NC, Berg T, Elena C, Casetti IC, et al. Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123(10):1544–1551. doi:10.1182/blood-2013-11-539098.
   PubMed Web of Science ®Google Scholar
• Mansier O, Luque Paz D, Ianotto JC, Le Bris Y, Chauveau A, Boyer F, Conejero C, Fitoussi O, Riou J, Adiko D, et al. Clinical and biological characterization of MPN patients harboring two driver mutations, a French intergroup of myeloproliferative neoplasms (FIM) study. Am J Hematol. 2018;93(4):E84–86. doi:10.1002/ajh.25014.
   PubMed Web of Science ®Google Scholar
• Thompson ER, Nguyen T, Kankanige Y, Yeh P, Ingbritsen M, McBean M, Semple T, Mir Arnau G, Burbury K, Lee N, et al. Clonal independence of JAK2 and CALR or MPL mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing. Haematologica. 2021;106(1):313–315. doi:10.3324/haematol.2020.260448.
   PubMed Web of Science ®Google Scholar
• Makishima H. Somatic SETBP1 mutations in myeloid neoplasms. Int J Hematol. 2017;105(6):732–742. doi:10.1007/s12185-017-2241-1.
   PubMed Web of Science ®Google Scholar
• Meggendorfer M, Bacher U, Alpermann T, Haferlach C, Kern W, Gambacorti-Passerini C, Haferlach T, Schnittger S. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia. 2013;27(9):1852–1860. doi:10.1038/leu.2013.133.
   PubMed Web of Science ®Google Scholar
• Hou HA, Kuo YY, Tang JL, Chou WC, Yao M, Lai YJ, Lin CC, Chen CY, Liu CY, Tseng MH, et al. Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression. Am J Hematol. 2014;89(2):181–186. doi:10.1002/ajh.23611.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A, Finke C, Score J, Gangat N, Mannarelli C, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27(9):1861–1869. doi:10.1038/leu.2013.119.
   PubMed Web of Science ®Google Scholar
• Guglielmelli P, Bartalucci N, Contini E, Rotunno G, Pacilli A, Romagnoli S, Mannelli L, Mannelli F, Coltro G, Pancrazzi A, et al. Involvement of RUNX1 pathway is a common event in the leukemic transformation of chronic myeloproliferative neoplasms (MPNs). Blood. 2019;134(Supplement_1):2968. doi:10.1182/blood-2019-129094.
   Google Scholar
• Sanada M, Suzuki T, Shih LY, Otsu M, Kato M, Yamazaki S, Tamura A, Honda H, Sakata-Yanagimoto M, Kumano K, et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature. 2009;460(7257):904–908. doi:10.1038/nature08240.
   PubMed Web of Science ®Google Scholar
• Laskowski RA, Stephenson JD, Sillitoe I, Orengo CA, Jm T. VarSite: disease variants and protein structure. Protein Sci. 2020;29(1):111–119. doi:10.1002/pro.3746.
   PubMed Web of Science ®Google Scholar
• Beer PA, Delhommeau F, LeCouédic JP, Dawson MA, Chen E, Bareford D, Kusec R, McMullin MF, Harrison CN, Vannucchi AM, et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood. 2010;115(14):2891–2900. doi:10.1182/blood-2009-08-236596.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Guglielmelli P, Lasho TL, Coltro G, Finke CM, Loscocco GG, Sordi B, Szuber N, Rotunno G, Pacilli A, et al. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br J Haematol. 2020;189(2):291–302. doi:10.1111/bjh.16380.
   PubMed Web of Science ®Google Scholar
• Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I, Girsberger S, Lehmann T, Passweg J, Stern M, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014;123(14):2220–2228. doi:10.1182/blood-2013-11-537167.
   PubMed Web of Science ®Google Scholar
• Rampal R, Ahn J, Abdel-Wahab O, Nahas M, Wang K, Lipson D, Otto GA, Yelensky R, Hricik T, McKenney AS, et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proc Natl Acad Sci USA. 2014;111(50):E5401–10. doi:10.1073/pnas.1407792111.
   PubMed Web of Science ®Google Scholar
• Partouche N, Conejero C, Barathon Q, Moroch J, Tulliez M, Cordonnier C, Giraudier S. Emergence of MPLW515 mutation in a patient with CALR deletion: Evidence of secondary acquisition of MPL mutation in the CALR clone. Hematol Oncol. 2018;36(1):336–339. doi:10.1002/hon.2431.
   PubMed Web of Science ®Google Scholar
• Bernal M, Jiménez P, Puerta J, Ruíz-Cabello F, Jurado M. Co-mutated CALR and MPL driver genes in a patient with myeloproliferative neoplasm. Ann Hematol. 2017;96(8):1339–1401. doi:10.1007/s00277-017-3023-9.
   Web of Science ®Google Scholar